

PHAYM055: Pharmacology 1 (Masters Level): Pharmacology and CNS disorders

[View Online](#)

1

Smith KS, Rudolph U. Anxiety and depression: Mouse genetics and pharmacological approaches to the role of GABAA receptor subtypes. *Neuropharmacology* 2012;**62**:54–62. doi:10.1016/j.neuropharm.2011.07.026

2

Luscher B, Shen Q, Sahir N. The GABAergic deficit hypothesis of major depressive disorder. *Molecular Psychiatry* 2011;**16**:383–406. doi:10.1038/mp.2010.120

3

Balon R. Mood, anxiety, and physical illness: body and mind, or mind and body? *Depression and Anxiety* 2006;**23**:377–87. doi:10.1002/da.20217

4

Kalueff AV, Nutt DJ. Role of GABA in anxiety and depression. *Depression and Anxiety* 2007;**24**:495–517. doi:10.1002/da.20262

5

Cryan JF, Kaupmann K. Don't worry 'B' happy!: a role for GABAB receptors in anxiety and depression. *Trends in Pharmacological Sciences* 2005;**26**:36–43. doi:10.1016/j.tips.2004.11.004

6

Holmes A, Heilig M, Rupniak NMJ, et al. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. *Trends in Pharmacological Sciences* 2003;**24**:580–8. doi:10.1016/j.tips.2003.09.011

7

Levine J, Cole DP, Chengappa KNR, et al. Anxiety disorders and major depression, together or apart. *Depression and Anxiety* 2001;**14**:94–104. doi:10.1002/da.1051

8

Freund TF. Interneuron Diversity series: Rhythm and mood in perisomatic inhibition. *Trends in Neurosciences* 2003;**26**:489–95. doi:10.1016/S0166-2236(03)00227-3

9

Strange PG. *Brain biochemistry and brain disorders*. Oxford: : Oxford University Press 1992.

10

Carvalho AF, Van Bockstaele EJ. Cannabinoid modulation of noradrenergic circuits: Implications for psychiatric disorders. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 2012;**38**:59–67. doi:10.1016/j.pnpbp.2012.01.008

11

Atwood BK, Straiker A, Mackie K. CB2: Therapeutic target-in-waiting. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 2012;**38**:16–20. doi:10.1016/j.pnpbp.2011.12.001

12

Hill AJ, Williams CM, Whalley BJ, et al. Phytocannabinoids as novel therapeutic agents in CNS disorders. *Pharmacology & Therapeutics* 2012;**133**:79–97. doi:10.1016/j.pharmthera.2011.09.002

13

Sodium oxybate: a primer for pharmacists in the treatment of narcolepsy.

https://www.researchgate.net/profile/Kimberley_Begley2/publication/265473606_Sodium_Oxybate_A_Primer_for_Pharmacists_in_the_Treatment_of_Narcolepsy/links/54dceb110cf25b09b912dd40.pdf

14

H. Attarian OA. Treatment of disorders of hypersomnolence. ;**16**

:302–302.http://download.springer.com/static/pdf/61/art%253A10.1007%252Fs11940-014-0302-9.pdf?auth66=1414068132_049751e80fe3aa485ba574ca1df01580&ext=.pdf

15

N.P. Robertson KJP. Narcolepsy: environment, genes and treatment. 2014;**261**

:1644–6.<http://link.springer.com.libproxy.ucl.ac.uk/article/10.1007/s00415-014-7435-3/fulltext.html>

16

Cera N, Tartaro A, Sensi SL. Modafinil Alters Intrinsic Functional Connectivity of the Right Posterior Insula: A Pharmacological Resting State fMRI Study. PLoS ONE 2014;**9**.
doi:10.1371/journal.pone.0107145

17

Saper CB, Scammell TE. Emerging therapeutics in sleep. Annals of Neurology 2013;**74**:435–40. doi:10.1002/ana.24000

18

Eric J. Olson KR. Management of common sleep disorders. 2013;**88**

:231–8.<http://www.aafp.org/afp/2013/0815/p231.pdf>

19

Hoyer D, Jacobson LH. Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand? Neuropeptides 2013;**47**:477–88. doi:10.1016/j.npep.2013.10.009

20

Carlos H. Schenck MWM. Insights from studying human sleep disorders. 2005;**437**:1279–85.<http://www.nature.com.libproxy.ucl.ac.uk/nature/journal/v437/n7063/pdf/nature04287.pdf>

21

Stores G. Medication for sleep-wake disorders. Archives of Disease in Childhood 2003;**88**:899–903. doi:10.1136/ad.88.10.899

22

Kilduff TS, Peyron C. The hypocretin/orexin ligand–receptor system: implications for sleep and sleep disorders. Trends in Neurosciences 2000;**23**:359–65. doi:10.1016/S0166-2236(00)01594-0

23

Brisbare-Roch C. Promotion of sleep by targeting the orexin system in rats, dogs and humans. 2007;**13**:150–5.<http://www.nature.com.libproxy.ucl.ac.uk/nm/journal/v13/n2/pdf/nm1544.pdf>

24

Mark W. Mahowald MD. Pathophysiologic mechanisms in REM sleep behavior disorder. Current Neurology and Neuroscience Reports 2007;**7**:167–72. doi:10.1007/s11910-007-0013-7

25

Mahowald MW, Schenck CH. Dissociated states of wakefulness and sleep. Neurology 1992;**42 Suppl. 6**:44–52.<http://ovidsp.uk.ovid.com/sp-3.29.1a/ovidweb.cgi?QS2=434f4e1a73d37e8cfb45f8f3b30e414ee9c0a99335d397e159343d518000931b3c02776b3f73d5a73a4476c2679e970ee9f9ae15361c4ac577ac7741a1d63634ffba5cef7d6361f976830f426efde734282833d172499d85065998d528dfa9b0a1521d75a5793939995cf8636d6af8a033f8955aa9e537d33ba711609a51d940e69485e1ed697cf1dadcd84e2eb68e50c7e93be01be19eed6df41603840c5460e69cc207bc2ddbc6eb8c2189f3a42a831e6ad6a1f92d7fa7471c844690e98333819a6b3170803>

3f7fb585a0e12b8a8ff8a4b15631fb49b82364902e6f027e3eebcba970b2989190824afdb92
1b41b4cbf09a5f9664093d267e01ea7087c5e48493339b1f5c17aed68251a3a1acd20e242d
6f05b7bf22829494401b04044f2cd3299f2879d54f2227f13dbe1ffabb7a65b8acf2bc248075
30aa2899ef11384d1b4fbf3817896b409736f1feff76969f4975dfd6acee872cc4ce58ece4230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2
8c7a4f7e5f403a33c1d53baed312e42693f7a1e0